{"id":1457,"date":"2026-05-26T08:16:39","date_gmt":"2026-05-26T13:16:39","guid":{"rendered":"https:\/\/elyxaminos.com\/producto\/5-amino-1mq-50mg\/"},"modified":"2026-07-27T09:32:50","modified_gmt":"2026-07-27T14:32:50","slug":"5-amino-1mq-50mg","status":"publish","type":"product","link":"https:\/\/elyxaminos.com\/en\/producto\/5-amino-1mq-50mg\/","title":{"rendered":"5-Amino-1MQ 50mg"},"content":{"rendered":"<section>\n<h2>5-Amino-1MQ 50mg<\/h2>\n<p><strong>Inhibidor NNMT \u00b7 Rescate NAD+ precl\u00ednico \u00b7 Research Only<\/strong><\/p>\n<h3>What is it and how does it work?<\/h3>\n<p>5-Amino-1-Metilquinolinio (5-Amino-1MQ) es una mol\u00e9cula peque\u00f1a (no p\u00e9ptido) \u2014 inhibidor selectivo y permeable de la enzima NNMT (Nicotinamida N-Metiltransferasa). La literatura precl\u00ednica documenta que el bloqueo de NNMT frena el consumo de SAM y nicotinamida, elevando NAD+ intracelular y reactivando la v\u00eda de salvataje, con efectos en modelos animales sobre actividad SIRT1, lip\u00f3lisis, supresi\u00f3n de lipog\u00e9nesis y reactivaci\u00f3n de c\u00e9lulas madre musculares senescentes.<\/p>\n<p>Evidencia primaria precl\u00ednica documentada en roedores: Neelakantan H et al. (2018) Biochem Pharmacol 154:161-171 (PMID 29183836) \u2014 estudio fundacional en ratones con dieta alta en grasa (DIO), 20 mg\/kg SubQ TID \u00d7 11 d\u00edas \u2192 reducci\u00f3n de peso corporal y masa adiposa blanca sin cambio en ingesta. Neelakantan H et al. (2019) Biochem Pharmacol 163:481-492 (PMID 30753815) \u2014 modelo de m\u00fasculo envejecido en rat\u00f3n, NNMTi reactiv\u00f3 c\u00e9lulas madre musculares senescentes con +~70% de torque pico en tibial anterior. Material de investigaci\u00f3n \u00fanicamente \u2014 sin uso humano aprobado por FDA.<\/p>\n<h3>Reconstitution and dosage<\/h3>\n<ul>\n<li><strong>Vial<\/strong> 50 mg lyophilized<\/li>\n<li><strong>Bacteriostatic water:<\/strong> 2 ml (tablet \u2014 standard rule would be 10 ml, doesn't fit in 3ml vial)<\/li>\n<li><strong>Resulting concentration:<\/strong> 25,000 mcg\/ml<\/li>\n<li><strong>Per unit U-100:<\/strong> 250 mcg \u00b7 verification: 25,000 \u00f7 100 = 250 mcg\/u \u2713<\/li>\n<li><strong>Conservation<\/strong> Refrigerate 2\u20138\u00b0C \u00b7 Use within 28\u201330 days after reconstituting<\/li>\n<li><strong>Performance<\/strong> Equivalent volume: 200 U-100 units per reconstituted vial<\/li>\n<\/ul>\n<h3>Volume Conversion Chart (U-100 syringe)<\/h3>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\" style=\"border-collapse: collapse;width: 100%\">\n<thead>\n<tr>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">U-100 equivalent<\/th>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">Volume<\/th>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">Charge<\/th>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">Verification<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 6px\">25 years old<\/td>\n<td style=\"padding: 6px\">0.25 milliliters<\/td>\n<td style=\"padding: 6px\">6,250 mcg (6.25 mg)<\/td>\n<td style=\"padding: 6px\">25 u \u00d7 250 mcg = 6,250 mcg \u2713<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 6px\">50 u<\/td>\n<td style=\"padding: 6px\">0.50 mL<\/td>\n<td style=\"padding: 6px\">12,500 mcg (12.5 mg)<\/td>\n<td style=\"padding: 6px\">50 u \u00d7 250 mcg = 12,500 mcg \u2713<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 6px\">100 u<\/td>\n<td style=\"padding: 6px\">1.00 mL<\/td>\n<td style=\"padding: 6px\">25,000 mcg (25 mg)<\/td>\n<td style=\"padding: 6px\">100 u \u00d7 250 mcg = 25,000 mcg \u2713 (\u00bd vial)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 6px\">200 u<\/td>\n<td style=\"padding: 6px\">2.00 ml<\/td>\n<td style=\"padding: 6px\">50,000 mcg (50 mg)<\/td>\n<td style=\"padding: 6px\">200 u \u00d7 250 mcg = 50,000 mcg \u2713 (vial completo)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Documented evidence in research literature<\/h3>\n<details>\n<summary><strong>Evidencia precl\u00ednica \u00b7 obesidad y composici\u00f3n corporal<\/strong><\/summary>\n<ul>\n<li>Neelakantan H et al., Biochem Pharmacol 2018 (PMID 29183836) \u2014 modelo DIO en rat\u00f3n macho C57BL\/6J, NNMTi 5-Amino-1MQ 20 mg\/kg SubQ TID \u00d7 11 d\u00edas \u2192 \u2193 peso corporal y \u2193 masa adiposa blanca<\/li>\n<li>Sin cambios significativos en ingesta cal\u00f3rica reportados \u2014 el efecto se atribuye a modulaci\u00f3n metab\u00f3lica directa, no anor\u00e9xica<\/li>\n<li>Conversi\u00f3n alom\u00e9trica rat\u00f3n\u2192humano (km 3 vs 37): 20 mg\/kg rat\u00f3n \u2248 1.6 mg\/kg HED \u2014 referencia traslacional te\u00f3rica \u00fanicamente<\/li>\n<\/ul>\n<\/details>\n<details>\n<summary><strong>Evidencia precl\u00ednica \u00b7 sarcopenia y reparaci\u00f3n muscular<\/strong><\/summary>\n<ul>\n<li>Neelakantan H et al., Biochem Pharmacol 2019 (PMID 30753815) \u2014 NNMTi reactiv\u00f3 c\u00e9lulas madre musculares senescentes en rat\u00f3n envejecido<\/li>\n<li>Mejora documentada: ~70% torque pico tibial anterior en modelo de rat\u00f3n viejo<\/li>\n<li>Mecanismo reportado: rescate del pool intracelular NAD+ v\u00eda bloqueo de NNMT<\/li>\n<\/ul>\n<\/details>\n<details>\n<summary><strong>Revisiones de mecanismo NAD+\/NNMT<\/strong><\/summary>\n<ul>\n<li>Roberti A et al. (2021) Front Endocrinol PMC8337113 \u2014 review &#8216;Roles of NNMT in Obesity and Type 2 Diabetes&#8217;<\/li>\n<li>Campagna R et al. (2024) Int J Mol Sci PMC11205546 \u2014 review &#8216;NNMT: A New Hope for Treating Aging and Age-Related Conditions&#8217;<\/li>\n<li>Modelo molecular: inhibici\u00f3n selectiva NNMT \u2192 \u2191 SAM intracelular + \u2191 nicotinamida \u2192 reactivaci\u00f3n salvataje NAD+ \u2192 \u2191 actividad SIRT1<\/li>\n<\/ul>\n<\/details>\n<h3>Combinations reported in literature<\/h3>\n<ul>\n<li>5-Amino-1MQ + MOTS-C en literatura precl\u00ednica: v\u00edas mitocondriales independientes \u2014 NNMTi rescata NAD+, MOTS-C activa AMPK y biog\u00e9nesis mitocondrial. Sin solapamiento mecan\u00edstico.<\/li>\n<li>5-Amino-1MQ + Tesamorelin\/CJC-Ipa: ejes independientes en investigaci\u00f3n \u2014 GH\/IGF-1 vs modulaci\u00f3n metab\u00f3lica v\u00eda NAD+\/SIRT1.<\/li>\n<li>5-Amino-1MQ + AOD 9604: lip\u00f3lisis directa (AOD) + bloqueo de lipog\u00e9nesis y rescate energ\u00e9tico (NNMTi) en modelos animales.<\/li>\n<li>5-Amino-1MQ + NAD+ inyectable: literatura reporta complementariedad \u2014 NNMTi corta la fuga v\u00eda metilaci\u00f3n de nicotinamida; NAD+ inyectable repone sustrato.<\/li>\n<li>5-Amino-1MQ + Retatrutide en literatura emergente: agonismo triple GLP\/GIP\/GCG + modulaci\u00f3n metab\u00f3lica NAD+\/SIRT1 en investigaci\u00f3n de composici\u00f3n corporal.<\/li>\n<\/ul>\n<h3>Practical notes<\/h3>\n<ul>\n<li>Mol\u00e9cula peque\u00f1a \u2014 NO es p\u00e9ptido. Quinolinium estable con alta permeabilidad de membrana. Vial 50 mg comprimido a 2 ml por l\u00edmite f\u00edsico de vial 3 ml \u2014 concentraci\u00f3n 25,000 mcg\/ml.<\/li>\n<li>Literatura primaria precl\u00ednica us\u00f3 administraci\u00f3n SubQ en rat\u00f3n (Neelakantan 2018, 2019). Gu\u00edas comerciales tipicamente citan administraci\u00f3n oral por practicidad de volumen en mam\u00edferos peque\u00f1os.<\/li>\n<\/ul>\n<h3>Contraindications and precautions<\/h3>\n<ul>\n<li>Material de investigaci\u00f3n \u00fanicamente. Sin uso humano aprobado por FDA. Toda evidencia es precl\u00ednica (rat\u00f3n). Sin datos de seguridad establecidos en humanos a largo plazo. No para uso humano.<\/li>\n<\/ul>\n<p><em><strong>Research material only. Not approved for human use by the FDA.<\/strong> This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.<\/em><\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p><strong>Inhibidor NNMT \u00b7 Rescate NAD+ precl\u00ednico \u00b7 Research Only<\/strong><\/p>\n<ul>\n<li>5-Amino-1-Metilquinolinio (5-Amino-1MQ) es una mol\u00e9cula peque\u00f1a (no p\u00e9ptido) \u2014 inhibidor selectivo y permeable de la enzima NNMT (Nicotinamida N-Metiltransferasa).<\/li>\n<li>La literatura precl\u00ednica documenta que el bloqueo de NNMT frena el consumo de SAM y nicotinamida, elevando NAD+ intracelular y reactivando la v\u00eda de salvataje, con efectos en modelos animales sobre actividad SIRT1, lip\u00f3lisis, supresi\u00f3n de lipog\u00e9nesis y reactivaci\u00f3n de c\u00e9lulas madre musculares senescentes.<\/li>\n<li><strong>Presentation<\/strong> 50 mg lyophilized lyophilized \u00b7 <strong>For research purposes only<\/strong><\/li>\n<\/ul>\n<p><!-- ELYX-CERT-BUTTONS:start --><\/p>\n<div style=\"display: flex;flex-wrap: wrap;gap: 8px;justify-content: center;margin-top: 16px;margin-bottom: 8px\">\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/05\/5AMINO1MQ_50MG_COA.pdf\" target=\"_blank\" rel=\"noreferrer\"><button style=\"display: flex;align-items: center;justify-content: center;background: linear-gradient(264.62deg, #02042B 11.77%, #0334D8 62.3%, #48DFE4 91.88%);padding: 12px 24px;border-radius: 50px;color: white;border: none;font-weight: bold;cursor: pointer;text-align: center;font-family: sans-serif;min-width: 130px\">Certificate of Analysis<\/button><\/a><br \/>\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/05\/5AMINO1MQ_50MG_ENDO.pdf\" target=\"_blank\" rel=\"noreferrer\"><button style=\"display: flex;align-items: center;justify-content: center;background: linear-gradient(264.62deg, #02042B 11.77%, #0334D8 62.3%, #48DFE4 91.88%);padding: 12px 24px;border-radius: 50px;color: white;border: none;font-weight: bold;cursor: pointer;text-align: center;font-family: sans-serif;min-width: 130px\">Endotoxins<\/button><\/a>\n<\/div>\n<p><!-- ELYX-CERT-BUTTONS:end --><\/p>","protected":false},"featured_media":1536,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[37,41],"product_tag":[],"class_list":{"0":"post-1457","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-fat-loss","7":"product_cat-metabolic-health","9":"first","10":"instock","11":"shipping-taxable","12":"purchasable","13":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product\/1457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/comments?post=1457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/media\/1536"}],"wp:attachment":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/media?parent=1457"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_brand?post=1457"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_cat?post=1457"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_tag?post=1457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}